medecinedesvoyages.net
Patrick GEROME, le 10/03/2026 (mis à jour le 11/03/2026)
An outbreak of Mpox continues to unfold in Madagascar, with 11 new confirmed cases reported as of March 10, 2026, according to the latest report from the country’s Ministry of Public Health. This ongoing situation highlights the importance of global surveillance and response to emerging infectious diseases.
To date, a total of 1,186 cases have been reported since December 18, 2025, with 539 cases confirmed across 37 districts.
Mahajanga remains the epicenter of the outbreak, accounting for 280 confirmed cases, representing 52% of the total. Antananarivo Renivohitra follows with 74 confirmed cases (14%), whereas Antananarivo Atsimondrano has reported 25 cases (5%), Toliara 22 cases (4%), and Fianarantsoa 15 cases (3%).
As of March 10, 2026, 374 patients have been declared recovered.
Tragically, the first death linked to the outbreak was confirmed on March 2, 2026. A 3-year-aged child died from the illness on the night of February 28 at the Cenhosoa hospital center. This underscores the vulnerability of young children to severe outcomes from Mpox.
In response to the growing epidemic, 30,000 doses of vaccine produced by Bavarian Nordic have arrived in the country to support prevention and control efforts. The vaccine received a favorable opinion from Madagascar’s Technical Advisory Group on Vaccination (GT-CV), in accordance with national procedures. These doses will facilitate a targeted vaccination campaign for populations most at risk, including frontline healthcare workers and individuals identified as vulnerable, as directed by health authorities.
Source: Flutrackers, Newsmada, franceinfo:, Unicef
Zones Associées: Madagascar
